In polycythemia vera (PV) and essential throbocythemia (ET), the JAK2 mutation can sustain a condition of chronic inflammation (1–3), explaining the associated constitutional symptoms, thrombosis, and premature atherosclerosis observed in patients with these disorders (4–6). Here, JAK2 is linked to essential thrombocythemia.